International Journal of Drug Regulatory Affairs

Comparative Study of Regulatory Requirement and Approval Process for Drugs in India, US and Europe

Suchita Anand Shirole — 2026-09-15

This review conducts a comparative analysis of drug approval for new and generic medicines across three jurisdictions: United States (US FDA), India (CDSCO), and the European Union (EMA) framed as a three-stage process (application, review, approval) and focusing on regulatory pathways, statutory timelines, documentation requirements, and application costs; it also compares review timelines and application costs across the three agencies. Primary data were gathered from official regulatory documents, guidelines, fee schedules, and the FDA, CDSCO (India), and EMA (current through mid-2025) agencies' websites. Secondary market data were procured from authoritative industry reports. Systematic search and cross verification of primary sources, taking into consideration the US Code of Federal Regulations (Titles 21 and 42), New Drugs and Clinical Trials Rules of India 2019, applicable rules, and Directives of the EU and procedural manuals of each agency. All jurisdictions, operationally, follow a three-stage approval process. The US FDA has high application costs, a 10-month standard review time, and many expedited pathways. India's CDSCO has low application costs, a prescribed 90-day review with a deemed-approval mechanism, and frequent waivers of local trials. The EMA's centralised procedure has an average lead time of 277 days and provides significant fee reductions to small companies and orphan drugs. All three use the eCTD for submissions, but the administrative details and form requirements differ.

Conclusion: Jurisdictional strategies are reflective of distinct priorities: the priority of the US for rigorous evaluation in high-value markets, the incentives of Europe for specialised therapies, and the priority of India on efficiency and cost-effectiveness are essential for drug development across the globe.

Electronic Product Information Leaflet (ePIL): Opportunities, Challenges, and Future Directions

Chaitanya Vitthal Shinde — 2026-09-15

The purpose of EPILs, the electronic version of the leaflets placed in pharmaceutical packaging, is to enhance patient understanding and information access. ePILs present a chance to optimize patient safety, engagement, and adherence as digital health continues to grow. The evidence that currently exists on patient preference, eHealth literacy, and ePIL adoption is examined in the following paper together with the positive aspects, difficulties, and potential implementation strategies. A qualitative examination of research from various nations shows that while ePILs improve accessibility and user satisfaction, issues with digital literacy, user interface, and trust still exist. There is consideration of the implications both for implementation in healthcare systems and futureresearch.

Conclusion: Electronic product information leaflets, or ePILs, give patients a better understanding of their medications and boost their confidence when taking them. However, problems like workflow integration and low digital literacy can limit their efficacy. Future studies should concentrate on vulnerable populations, long-term effects, and explicit regulations. When used appropriately, ePILs can enhance health literacy, safety, and adherence.

Regulatory Approval of Ferric Carboxy Maltose Injection 50mg/ml: A Comparison Across South Africa, Singapore and Saudi Arabia

Nikunj Sureliya — 2026-09-15

The regulatory approval Procedure for iron formulation, like Ferric Carboxy Maltose injection 50mg/ml , differs among international health authorities because to variation in evaluation schedules, dossier requirements, and reliance mechanisms The registration process and legal frameworks controlling the approval of ferric carboxy maltose in South Africa, Singapore and Saudi Arabia are compared in this paper The Common Technical Document Format used in South Africa by the South Africa Regulatory Authority If the product approved by strict regulatory bodies, it may use a reliance approach through an abridge or verified review for items registered by reference agencies , Singapore's through an abridged or verified review for items by reference agencies Singapore's Health Sciences Authority (HSA) allows submission thorough verification or abridged evaluation Route, allowing the faster access. Saudi Regulatory Authority permit dependence FDA or EMA approvals via the Shortened registration procedure and adheres to GCC-CTD Framework the Comparative analysis emphazies regional variation in data expectations, stability circumstances, and labelling requirements while highlighting the growing global harmonisation through dependency models. Improving regulatory convergence and reliance frameworks can improve the patient access to high-quality injectable iron supplements and maximize review efficiency.

Conclusion: South African Regulatory Authority, Health Science Authority and Saudi Food Drug Regulatory Authority show differences in Timelines, dossier formats, and local Requirements for Ferric Carboxy Maltose Injection approval. However, all three are used Reliance Pathways based on approval of reference agencies Despite Regional variation this sifts supports global harmonization Strengthening Reliance Models can improve efficiency and faster patient access.

Comparative Evaluation of Regulatory Registration & Approval Pathways for Semaglutide 14 mg Tablet in Emerging South American Markets: Chile, Peru and Bolivia

Vishesh Modi — 2026-09-17

The regulatory registration and approval processes for semaglutide tablets 14 mg in Chile, Peru, and Bolivia—three developing South American markets—are compared in this paper. Regulatory bodies, dossier specifications, submission processes, review schedules, labelling requirements, and post-approval variances are all examined in the analysis. The results show that the three nations' technical documentation, GMP certification standards, language requirements, and approval procedures differ from one another. Bolivia retains a more administrative and mostly offline submission method, whereas Chile and Peru adhere to more structured regulatory frameworks with components that are in line with international norms. In order to facilitate effective market entrance planning and compliance in developing South American pharmaceutical markets, this comparison offers key regulatory insights.

Conclusion: The investigation reveals significant variation in Chile, Peru & Bolivia s Semaglutide market Regulatory Frameworks, particularly with regard to documentation, submission process & Compliance Bolivia has a more Manual Method Whereas Chile and Peru adhere to more Standarized, globally aligned systems. For an efficient registration Strategy and seamless market entry, these distinctions are essential.

Regulatory Frameworks for Strengthening Pharmaceutical Supply Chain Security: A Comparative Analysis of EU-FMD and US-DSCSA

Isha Makadia — 2026-09-17

False and counterfeit drugs are a significant worldwide medical danger especially in low and middle incomes where up to 1 out of 10 Medicines can be of inferior quality. Drug safety is also becoming hard to ensure through increased globalization and complexity of supply chains. Laws such as EU-FMD or US-DSCSA help to solve such problems by implementing the system of serialization, verifying, and tracing. At the same time, the centralized verification clarifies the concept of FMD, whereas DSCSA dwells upon end-to-end track-and-trace mechanisms. All these structures contribute to transparency and allow avoiding false medicines penetrating into the supply chain.

Conclusion: EU-FMD and US-DSCSA offer huge improvements in the supply chain security of the pharmaceutical; this is achieved by serialization, traceability, and verification systems. Even though their methods are not the same, both frameworks are successful in ensuring a decrease in the chances of falsified medicines. Ongoing technology innovation and harmonization of regulations across the globe are indispensable towards improvement in the future.

Navigating Regulatory Diversity: A Comparative Study of Drug Product Registration Frameworks in Malaysia, Ghana, Kuwait and India

Khushi Hiteshkumar Gor — 2026-09-17

Pharmaceutical products have to follow a set of rules that will eventually prove their quality, effectiveness, and safety before they can be sold in the market. However, it is important to note that the process and requirements, such as what is needed from the manufacturer, differ from one country to another. This is a problem for companies that want to register their products in several countries. The aim of this research project is to compare and highlight the regulation of drug product registration in Malaysia, Ghana, and India, as well as the role of the regulatory authorities in these countries and the steps that will be undertaken by companies in order for their products to gain marketing authorisation. There are four major areas that we are going to discuss in detail: what documents are required to be submitted to each country, how each country will evaluate the documents that are submitted to them for approval, the timeframe to get approval from each country, and what document are required to be prepared to get approval. The regulatory process in Malaysia follows the ASEAN common technical dossier (ACTD), whereas in Ghana and India, it follows a different system. In addition to that, some of the similarities and dissimilarities that exist in the regulatory process of both countries will also be addressed in this research. Moreover, it will also highlight how these dissimilarities will create a problem in the expedited approval of product registration services to firms. Finally, it will highlight some of the challenges that pharmaceutical firms are likely to face in a different regulatory environment. The results of the research would be beneficial for the international drug regulatory professionals. It would be beneficial for the researchers of international drug registration. In the end, the significance of the comprehension of the diversity of regulations would be highlighted.

Conclusion: The review also explains a brief about different regulatory requirement for Registration of drug product in Malaysia, Ghana, India and Kuwait. And also, comparative data for registration of dossier application in Malaysia, Ghana, India and Kuwait.

Regulatory Trends and Challenges in Pharmaceutical Submissions: A Critical Analysis of Health Authority Requirements on Nitrosamine Impurities, Elemental Impurities, Forced Degradation and Genotoxicity

Darshan Mistry — 2026-09-17

As the control of pharmaceutical impurity directly influences the patient safety and quality of the product, it has become a part and parcel of the contemporary drug regulation. Regulatory agencies worldwide have responded to recent outbreaks of nitrosamine contamination and increased scientific understanding of the genotoxic and elemental impurities by increasing the demands on impurity testing. This paper evaluates regulatory anticipations of impurity management within pharmaceutical submissions in terms of elements of nitrosamine impurities, genotoxic impurities, forced degradation, and elemental impurities. Some of the major health authorities that have put regulatory frameworks in place include the United States Food and Drug Administration (USFDA), the European Medicine Agency (EMA), and the Central Drugs Standard Control Organization (CDSCO). A comparative study of these frameworks was carried out based on harmonized guidelines that were released by the International Council for harmonization (ICH). Some of the practical case studies conducted were the assessment of elemental impurities in Atracurium Besylate in line with the ICH Q3D, the risk assessment of nitrosamine impurities in Minocycline Hydrochloride and forced degradation studies of Prednisolone under different stress conditions. The analysis was performed by the analytical procedures such as inductively coupled plasma mass spectrometry (ICP-MS) and high-performance liquid chromatography (HPLC). The results revealed that elemental impurities and detected nitrosamine were within regulatory level and were not in the tested batches. According to the results, regulatory harmonization and risk-based impurity control methods are important in the safety and compliance of pharmaceutical products.

Conclusion: Pharmaceutical safety and regulatory compliance require the effective management of impurities. This paper shows that the compliance with harmonized ICH requirements and regulatory frameworks (USFDA, EMA, CDSCO) allows managing impurities reliably. The analytical findings indicated that the levels of nitrosamine and elemental impurities were not beyond acceptable levels. Also, forced degradation tests were used to aid in stability testing and methodology development. In general, the risk-based and science-driven strategy is a necessary method to sustain the quality of the product.

Decoding FDA Complete Response Letters: Regulatory Challenges and Strategies for Successful Drug Approval

Mukti Kapdi — 2026-09-17

A Complete Response Letter (CRL) is provided by the U.S. Food and Drug Administration (FDA) when a marketing application is deemed unprovable in its existing format. Although CRLs hold important regulatory implications, there is a lack of comprehensive analytical frameworks for their assessment. To develop a systematic analytical framework with CTD standards for the identification, classification, and assessment of deficiencies found in FDA Complete Response Letters (CRLs). As such, an established analytical model that was mainly used for FDA Warning Letters is adapted to fit the diagnostic framework employed for CRLs assessment. Found deficiencies were categorised according to the CTD framework, which enabled a systematic distribution in diverse fields — CMC (Module 3), Clinical data (Module 5), Nonclinical information, Labelling requirements, Facility Inspections, Drug–Device Combinations. The methodology utilised thematic grouping and trend analysis to identify ongoing regulatory concerns. Frequent deficiencies included inadequate analytical validation, weak impurity and heavy metal controls, insufficient dissolution data, clinical efficacy failures, safety concerns, labelling non-compliance, and gaps in biocompatibility, extractables/leachable evaluation, and bridging studies. A framework built on CTD enhances the interpretation of CRL, boosts the quality of submissions, identifies potential risks, and fortifies readiness for regulatory compliance in future applications.

Conclusion: The study highlights that major deficiencies in USFDA drug approval submissions, particularly in CMC and clinical areas, are commonly associated with poor data quality, inadequate validation, incomplete documentation, and insufficient safety and efficacy evidence. A systematic, proactive approach incorporating CTD guidelines, deficiency tracking, quality-focused processes, and cross-functional collaboration can improve submission quality, reduce regulatory risks, and facilitate faster patient access to approved therapies.

A Comparative Analysis of Drug Marketing Authorization Procedures in Canada and the European Union

Vinuthna Rallapalli — 2026-09-17

The current study will offer an extensive comparison of drug marketing authorization systems within the European Union (EU) and Canada. It examines and compares the regulations, submission procedures, the availability of scientific advice, the type of review, the approving authorities, and the post-review requirements followed in Health Canada and the European Medicines Agency (EMA). Even though both territories adhere to ICH conventions and require CTD/eCTD formats, there are essential distinctions between accelerated approval programs, including Canada Priority Review and Notice of Compliance with Conditions (NOC/c), and the EU Accelerated Assessment, Conditional Approval, and PRIME programs. An overall comparison of procedures is in the form of a table showing differences in structure. In order to evaluate the real-life implementation, three case studies with the most common diseases, Keytruda (oncology), Spinraza (orphan/rare disease), and Humira biosimilar (biologic), were chosen, comparing regulatory approaches and approval dates. The results can be confirmed with the tables and graphs to prove the trends in the approval timelines. It can be concluded that Canada had earlier access to the oncology treatment given in advance through Priority Review, as happened with Keytruda, and the EU was ahead in approval of orphan and biosimilar drugs, having Spinraza and Humira as their representatives. What is captured by these trends is the various strategic focuses and maturity of the regulatory systems. A further analysis of their differences and resulting regulatory planning, when to submit, and the commercial launch of products is also discussed. The insights can help pharmaceutical companies customize region-specific regulatory approaches on the basis of the type of drug and therapeutic area. The recommendation at the end is the adaptability and cross-regional knowledge in the regulations to allow more efficient access for patients to innovative therapies.

Conclusion: This review article eventually offers a useful guide to interested parties in terms of international drug development, regulatory relations, and market access strategy.

Comparative Evaluation of Nitrosamine Impurity Control Strategies in USFDA, EMA, and WHO Pharmaceutical Submissions

Subalakshmi K — 2026-09-17

Nitrosamine impurities are of significant concern to the pharmaceutical industry because of their genotoxic and carcinogenic effects. They are formed during the manufacturing, storage, and/or packaging of APIs and/or drug products owing to the nitrosation reactions of amines with nitrosating reagents. The detection of nitrosamine impurities, such as N-nitrosodimethylamine and N-nitrosodiethylamine in medicinal products, including angiotensin II receptor blockers, ranitidine, and metformin, has raised significant concerns in the industry. Regulatory agencies have developed guidelines for controlling nitrosamine impurities. This review aims to evaluate the guidelines developed by the United States Food and Drug Administration, European Medicines Agency, and World Health Organization for controlling nitrosamine impurities and to identify the similarities and differences in the guidelines developed by the above agencies and the literature for risk evaluation, testing, and limits of intake, detection, and control of nitrosamine impurities. The review highlights the importance of strengthening international cooperation and developing standardised control strategies for the control of nitrosamine impurities in medicinal products, which is of significant importance for the quality and safety of medicinal products worldwide.

Conclusion: Effective control of nitrosamine impurities requires harmonized global guidelines, robust risk assessment, and advanced detection strategies to ensure the safety and quality of pharmaceutical products. Strengthening international collaboration is essential for developing consistent and reliable control measures worldwide.

Navigating Global Regulatory Frameworks: A Review of Submission Frameworks, Approvals and Timelines Across the FDA, EMA and MHRA

Vijayalakshmi Deivasikamani — 2026-09-17

Launching new pharmaceutical drugs is a complex, multi-phase process involving years of research and development. Regulatory approval is critical for ensuring that medicinal products meet rigorous standards of safety, efficacy, and quality. In the drug development lifecycle, clinical trial and marketing authorisation submissions represent pivotal regulatory milestones in the journey of a drug from research to commercialisation. This review focuses on navigating the regulatory submission frameworks, documentation, and timelines for the approval of clinical trials and marketing authorisation across the FDA, EMA and MHRA. Real-world clinical trials of some drugs have been analysed in this review as case studies, and the regulatory authority decisions have been compared to identify the key requirements for successful clinical trial and marketing authorisation applications. The review reveals that the FDA, EMA and MHRA are regulated globally by the ICH guidelines, specific regional regulations, and similar documentation requirements, but differ in their submission, review processes, approaches to evidence/endpoints, risk tolerance and timelines. The FDA adopts a relatively flexible approach, accepting single-arm trials with surrogate endpoints to support accelerated approval, with subsequent confirmatory studies required to verify clinical benefit. In contrast, the EMA operates a conservative, evidence-based framework that generally favours comparator-controlled trials and robust clinical endpoints, with conditional approvals subject to stringent obligations and annual review. Post-Brexit, the MHRA operates a hybrid model that combines EMA-style conditional approvals and reliance pathways that facilitate the recognition of decisions from other regulatory authorities, thereby increasing both regulatory agility and review efficiency.

Conclusion: Differences in regulatory agency approvals have important implications for global drug development programs, and efforts are underway to harmonise drug approval processes globally.